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A Patient-Centered Perspective*Courtenay R. Bruce, JD, MA,y Jennifer S. Blumenthal-Barby, PHD,y Deborah Meyers, MDzS everal studies describe the beneﬁts of leftventricular assist device (LVAD) therapy forthe “sickest of the sick” heart failure (HF)
patients with INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) proﬁles
1 to 3, for whom therapeutic options have been
exhausted (1–5). The ROADMAP (Risk AssessmentSEE PAGE 1747and Comparative Effectiveness of Left Ventricular
Assist Device [LVAD] and Medical Management)
study, published in this issue of the Journal, asks
whether these beneﬁts could extend to New York
Heart Association functional class IIIB/IV patients
who are not inotrope-dependent and who are less
sick, with INTERMACS proﬁles 4 to 7 (6). ROADMAP
is the ﬁrst prospective, nonrandomized, obser-
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to disclose.patients with advanced, noninotrope-dependent
ambulatory HF, treated with either optimal me-
dical management (OMM) or a HeartMate II LVAD
(Thoratec Corporation, Pleasanton, California). Key
ﬁndings include: 1) similar survival rates between
the LVAD and OMM groups, as reﬂected in the
intent-to-treat analysis; 2) low operative mortality
of 1%; 3) adverse events are more common in LVAD
patients versus OMM; and 4) functional status and
quality-of-life is better with LVAD patients compared
with the OMM group.
A limitation of the ROADMAP study is that in-
vestigators emphasized the importance of discussing
LVAD placement earlier within the HF illness, but
they did not discuss the implications of doing so,
which include communication and decision-making
challenges associated with earlier LVAD referrals.
Additionally, they do not provide patients’ perspec-
tives on early device introduction or discuss impor-
tant factors that should be integral to the risk/beneﬁt
analysis and clinician-patient communication. The
aim of this commentary is to serve as a companion
piece to the ROADMAP study by ﬁlling in these gaps.
In doing so, we use data from our large, federally-
funded study on how LVAD candidates, recipients,
and their family members make decisions about
LVAD placement. Findings were derived from struc-
tured interviews with: 1) patients considering LVAD
placement; 2) patients with LVADs; 3) family care-
givers of LVAD patients; and 4) decliners of LVAD
placement (7).
We caution against interpreting the ROADMAP
study’s results in a way that would favor LVAD
placement as default practice for patients with
less advanced HF. Rather, we advocate for a more
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1763nuanced interpretation of the ﬁndings: LVAD
placement is a highly preference-sensitive decision;
it involves a number of risk-beneﬁt tradeoffs
among mortality, adverse events, and functionality
that require robust clinician-patient dialogue early
in the course of patients’ illnesses to allow for
preference-congruent decisions. In weighing these
3 tradeoffs, some patients may elect to delay
or decline LVAD therapy to avoid LVAD-related
adverse events.
BENEFITS OF SHIFTING THE LVAD PARADIGM
TOWARD EARLY REFERRAL
Under the current paradigm, the majority of patients
living with an LVAD experienced cardiogenic shock or
were supported with inotropic support or intra-aortic
balloon pump at the time of implantation (8). In
support of the ROADMAP study’s ﬁndings about the
beneﬁts of earlier referral, approximately 40% of our
patient and caregiver interviewees said this was too
late, such as LVAD Recipient #107: “Why, at the
[outside] hospital, did it take so long? Why did they
let me suffer so many years and get shocked that
much, when I could have gotten the device when I
was stronger? Why did they wait until I about died
before they would give me one?” (7).
Patients, caregivers, and decliners uniformly re-
ported that hearing about the device earlier in the
course of their illness would mitigate feeling that the
decision-making process is rushed, as described by
LVAD Candidate #201: “After the [transfer to the
LVAD program], the evaluation went quick, fast, and
in a hurry. This told me [something] about the ur-
gency of my condition. I thought we were going to
wait 3 months until [LVAD placement]. They said,
‘No, this week’” (7).
Patients tend to make decisions about LVAD
placement reﬂexively, which is exacerbated if the
evaluation process is perceived as being “hurried”
(7,9–11). Patients and caregivers may be unable
to fully receive information, recalibrate, and adjust
to the emotional aspects associated with their
sickness or have time to deliberate on treatment
choices. Introducing the LVAD for less-sick cohorts
allows for iterative disclosures and clariﬁcations
over time.
One positive consequence of introducing the LVAD
option to patients with INTERMACS proﬁles 4 to 7 (as
opposed to just INTERMACS proﬁles 1 to 3) is that
patients and their families might perceive “a treat-
ment choice,” which they currently perceive as ab-
sent, as illustrated by this statement by Caregiver
#404: “By the time we got [to the LVAD center], theyhad to do it, or he would have died. There really
wasn’t a choice,” and also by Recipient #103, “I had
little choice, because I was so sick” (7).
CHALLENGES IN SHIFTING THE PARADIGM
TOWARD LESS ADVANCED HF
TIMING AND CONTENT OF DEVICE INTRODUCTIONS.
There are practical and ethical considerations asso-
ciated with earlier consideration of LVAD placement.
Importantly, there are open questions of which
cardiologist (referring or receiving) should introduce
the LVAD option, at what time, and what should be
the content of the initial discussion. Our interviewees
reported considerable variability, with about 60% of
respondents reporting that the device was not dis-
cussed until the patient was transferred to the LVAD
program. The remaining 40% or so said it was intro-
duced by the outside referring hospital, with varying
degrees of accuracy, as reﬂected through this care-
giver’s comment (#004): “The doctor at the [outside]
hospital told us to go to transplant. He said [the pa-
tient’s] heart was too weak, and that he would die on
the table [from an LVAD]. The doctor here [at the
LVAD program] had a completely different perspec-
tive” (7).
Some of the interviewees reported that outside
hospitals were not aware of the LVAD as an option
(Caregiver #004: “The doctor said there is nothing
more they can do. I knew about Dick Cheney, and so
I got online and started looking stuff up, and that’s
when I found out about the [LVAD center] [7].”
Other interviewees reported that referring cardiolo-
gists were familiar with the device, but they were
unable to adequately describe it. (Candidate #210:
“My [referring] cardiologist brought up the LVAD.
Well, he was trying to explain it, and he said that,
once I got to the LVAD [center], they would explain
it better” [7].)
These comments conﬁrm that patients encounter
mixed messages between referring and receiving
cardiologists. We suggest that referring cardiolo-
gists introduce the idea that specialized centers
exist that can provide additional therapies for
selected patients with advanced heart failure and
facilitate transfer for evaluation. We support pa-
tients receiving center-speciﬁc information upon
referral to the LVAD center detailing the risks and
beneﬁts of LVADs.
TREATMENT EXPECTATIONS. Accepting patients for
evaluation can be interpreted by patients or their
families as an implied commitment to maximally
treat or creating “buy-in” between clinicians and pa-
tients. (Caregiver #004: “When [he was accepted for
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1764transfer], we had something to hold on to, and we had
had a chance, because we had options” [7].)
Managing patients’ and family members’ expecta-
tions is critical (12). We suggest that both referring
and receiving centers undertake the following steps
to manage expectations:
1. Referring clinicians should reinforce that LVAD
evaluation will need to take place and that candi-
dacy cannot be ensured until a full evaluation is
complete.
2. The receiving LVAD center should attempt to
screen candidates via discussions with the refer-
ring physician and evaluate medical records with
the aim of avoiding bringing patients to the LVAD
center with clear contraindications for LVAD
therapy.
3. Upon arrival at the LVAD center, patients and
families should receive written information per-
taining to LVAD evaluation criteria and evaluation
processes, and the LVAD center team should
clearly reinforce this information by reviewing the
material with patients and families.
DECLINATION AND PERCEPTIONS OF ILLNESS
SEVERITY. A ﬁnal practical and ethical challenge
that we, like others, have found is that a key factor
inﬂuencing eligible candidates’ declinations of
LVAD treatment is that patients often underesti-
mate their illness severity (9–11). This is particularly
the case when they are on OMM, which provides a
false sense of security that they are healthier than
clinical parameters indicate. This is the case
regardless of education level. If the ROADMAP study
leads to a broader acceptance of earlier introduction
of device placement, an important question is
whether more patients will decline LVAD placement
because they “feel well.” Our recommendation is to
continually revisit LVAD declination decisions over
time, using subjective and objective indicators of
disease progression as “triggers” for revisiting
declination.CONCLUSIONS
The ROADMAP study encourages the LVAD commu-
nity to consider earlier introduction of LVADs to
patients with less-advanced HF. Although we agree,
we also recognize and describe several challenges in
introducing the device earlier in the HF trajectory.
To offset potential challenges, we provide several
recommendations to enhance patient selection, ed-
ucation, and decision-making processes, including:
1) having collaborative discussions between referring
and LVAD-center cardiologists before transfer to
manage patients’ and families’ expectations and
streamline information; 2) tracking LVAD declination
rates post-ROADMAP study to see if declination rates
signiﬁcantly increase above the current w10% (of all
eligible LVAD candidates) (11); 3) revisiting patients’
declination decisions with them; and 4) creating
center-speciﬁc written information on LVADs, the
patient selection evaluation process, and how can-
didacy determinations are made.
Our emphasis on early and iterative clinician-
patient discussion and patient-centered decision-
making takes on greater importance with the August
5, 2015, alert from the U.S. Food and Drug Adminis-
tration about serious adverse events associated with
LVADs (13). The U.S. Food and Drug Administration
alert underscores just how preference-sensitive de-
cisions about LVAD placement are and how tradeoffs
among mortality, adverse events, and functionality
need to be carefully weighed.
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